Skip to main content
Rafael Morales-Barrera on Muck Rack

Rafael Morales-Barrera

As seen in: Nature, MDPI, JAMA Oncology, European Urology, Cancer Treatment Reviews
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rafael

Contact Rafael, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression

|
By Fabio Turco, Silke Gillessen, Giuseppe Salfi, Niven Mehra, Matthew Labriola, Daniel George, Amanda Broderick, Anna Patrikidou, Consuelo Buttigliero, Veronica Crespi, Hirotsugu Uemura, Kazutoshi Fujita, Takanobu Utsumi, Hiroyoshi Suzuki, Daniele Raggi, Umberto Basso, Rafael Morales-Barrera, Cora Sternberg, Daniela Guevara Verified, Orazio Caffo, Giuseppe Procopio, Andrea Zivi, Sara Merler, Daniel E. Spratt, Pedro Barata, Carlo Messina, Yuksel Urun, Hatice Bolek, Ignacio Duran, Nieves Martinez Chanzá, Lisa G Horvath, Rhiannon Mellor, Sabrina Rossetti, Richard Cathomas, Giuseppe Banna, Vincenza Conteduca, Margaret Ottaviano, Laura Marandino, Hui-Ming Lin, Luigi Tortola, Ricardo Mestre, Martino Pedrani, Iris S. H. Kloots, Peter H. J. Slootbeek, Hortense Patry, David Marmolejo Castaneda, Mariella Sorarù, Merve Bengisu Soykök
| Nature Verified
Abstract Androgen deprivation therapy (ADT) + androgen receptor pathway inhibitor (ARPI)  ± docetaxel represent the standard of care in patients with metastatic hormone-sensitive prostate cancer (mHSPC). However, some patients still have early progression (EP). EMETPRO is a multicentric, retrospective registry of patients with EP mHSPC. Patients with EP mHSPC were defined as patients who had progression ≤6 months under ADT+docetaxel or ADT + ARPI or ≤9 months from ADT monotherapy start.
Open in Who Shared Issue with article?

Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer

|
By Randy F. Sweis, Rafael Morales-Barrera, Andrea Necchi, Pablo Gajate
| JAMA Oncology Verified
Key Points Question Can rogaratinib be safely combined with anti–programmed cell death 1 ligand 1 therapy to improve efficacy for patients with advanced/metastatic urothelial carcinoma harboring FGFR3 messenger RNA overexpression?
Open in Who Shared Issue with article?

Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration-resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial

|
By Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, Rafael Morales-Barrera
| European Urology Verified
Evaluation of bone metastasis in metastatic prostate cancer (mPC) remains a clinical challenge, as computed tomography and bone scans are unable to capture the response of these metastases to therapy. This is relevant for patient management and drug development, as radiographic response is a common intermediate endpoint in phase 1/2 clinical trials [].
Open in Who Shared Issue with article?
See all 6 articles